Noradrenergic control of vulnerability to chronic stress: novel mechanisms and targets

去甲肾上腺素能控制慢性应激的脆弱性：新机制和目标

• 批准号: 401510
• 负责人: Giros Bruno J
• 金额: $ 64.37万
• 依托单位: CIUSSS de l'Ouest-de-l'Ile-de-Montral-Douglas Hospital
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-03-01 至 2024-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=401510&lang=en
• 关键词: Antidepressant; Chronic Social Defeat; Chronic Stress; Depression; Dopamine; In Vivo Calcium Imaging; Noradrenaline; Noradrenergic Receptors; Resiliency

Depressive disorders are common and debilitating conditions affecting about 20% of people in North America within their lifetime. Despite some effective treatments, roughly one third of depressive patients are treatment-resistant. It is well known that

抑郁症是一种常见的、使人衰弱的疾病，在北美约有20%的人在其一生中受到影响。尽管有一些有效的治疗方法，但大约三分之一的抑郁症患者对治疗有抵抗力。 众所周知的是